Previous 10 | Next 10 |
2024-03-12 07:45:49 ET More on Pfizer Pfizer: A Strong Buy Trading Below A 10 P/E Ratio Pfizer Inc. (PFE) TD Cowen 44th Annual Health Care Conference 6%-Yielding Pfizer Is An Ultra-Deep-Value Gem In An Expensive Market Biden to push for expanding Medicare dru...
2024-03-05 09:54:23 ET Summary Takeda wins FDA approval for the first oral treatment for Eosinophilic esophagitis (EoE) in the US. The market size for EoE is expected to reach $941.8 million by 2031. Takeda's new CFO, Milano Furuta, will focus on growth and increasing sharehol...
Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda’s Ability to Deliver 100 Million Doses Per Year by 2030 At the Latest Addresses the Specific Need to Offer Multi-Dose Vials for National Immunization Programs to Help Protec...
Championing Rare Voices on Rare Disease Day Canada NewsWire 1 in 12 Canadians will be impacted by rare disease in their lifetime 1 I Am Number 12 campaign continues to drive action for rare disease community TORONTO , Feb. 26, 2024 /CNW/ - ...
2024-02-13 01:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-12 14:38:53 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call Presentation Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript CRISPR CMO who resigned after Casgevy approval lands...
— 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older — EoE Is a Chronic Disease That Can Significantly Impact Patients, with Esophageal Inflammation and Intermittent Symptoms of Choking and Difficult or ...
− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial − TAK-861 Was Found to be Generally Safe and Well-Tolerated − Results Will be Presented at an Upcoming Scientific Congress Takeda ( TSE:4502/NYSE...
2024-02-02 17:11:18 ET More on CRISPR Therapeutics, Takeda Pharmaceutical, etc. Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off ...
2024-02-02 11:17:26 ET More on WisdomTree Japan Hedged Equity Fund: DXJ: Capitalizing On Japan's Bull Market, Mitigating FX Risk DXJ: Forward Indicator Is Showing Signs Of Weakness Tsunami warning in Japan after earthquake; Trading closed for New Year's Seeki...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Pharmaceutical Company Limited American Depositary Shares Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
2024-07-04 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members servi...